People with metastatic or locally advanced bladder cancer may soon have a new treatment option and some clarity about which of two standard regimens to choose, according to two new studies presented this week at the virtual meeting of the European Society for Medical Oncology (ESMO).Interim results from one of the studies presented at ESMO found that the drug combination of Balversa (erdafitinib) and cetrelimab is producing meaningful responses in people with newly diagnosed bladder cancer whose cancer has a genetic alteration that renders standard chemotherapy less effective.The other study found that a multidrug chemotherapy cocktail yielded better tumor control after three years than the standard regimen of gemcitabine and cisplatin in people whose bladder cancer had spread into nearby muscle.The first study, known as NORSE, aims to provide a…